Sign in
LH

LifeStance Health Group, Inc. (LFST)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 delivered above-guide results: revenue $325.5M (+16% y/y), Center Margin $109.4M (+31% y/y), and Adjusted EBITDA $32.8M (+62% y/y), each exceeding the company’s Q4 guidance ranges, with first-ever double-digit quarterly Adjusted EBITDA margin of 10.1% .
  • FY 2024 capped strong execution: revenue $1.251B (+19% y/y), Center Margin $402.4M (+33% y/y), Adjusted EBITDA $119.7M (+103% y/y), Free Cash Flow $85.7M; 2025 guide calls for $1.40–$1.44B revenue, $130–$150M Adjusted EBITDA, and continued positive FCF .
  • Strategic catalysts: CEO transition (CFO Dave Bourdon to CEO; Ken Burdick to Executive Chairman) and debt refinancing that lowered the credit spread to 2.25% (from 3.75%), with >$4M annual interest savings .
  • Near-term headwinds: final rate decrease from one outlier payer and clinician compensation increases keep rates roughly flat in 2025, offset by operating leverage; management targets margin expansion again in 2026 with a path to 15–20% EBITDA margins and positive net income in FY 2026 .

What Went Well and What Went Wrong

What Went Well

  • Revenue, Center Margin, and Adjusted EBITDA all beat Q4 guidance, with margin reaching 10.1%—a first as a public company; drivers included higher total revenue per visit and improved clinician productivity .
  • Free cash flow and collections improved materially: Q4 FCF $56.0M, DSO down 10 days sequentially to 37 days, aided by operational discipline despite industry-wide collections disruption from the Change Healthcare cyberattack .
  • Strategic positioning strengthened: CEO transition to Dave Bourdon, readiness to re-engage in disciplined M&A, and refinancing that reduces annual interest expense by >$4M and doubles revolver capacity to $100M .
    • “We once again beat on all of our guided metrics… adjusted EBITDA up 103% to $120 million… we feel well positioned to deliver on our 2025 commitments.” — Ken Burdick

What Went Wrong

  • Rate headwind persists: final of three rate decreases from a single outlier payer will weigh on TRPV in early 2025, keeping payer rates roughly flat for the year .
  • G&A stepped up in Q4 (about $5M pulled-forward investments and clearing one-time items), with payroll taxes causing a Q1 seasonal spike; clinicians’ compensation increases pressure center margin in 2025 before G&A leverage offsets .
  • Cost per visit declines from 2024 real estate consolidation are not expected to repeat in 2025; unit costs rise with clinician compensation adjustments .

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$312.3 $312.7 $325.5
Net Loss ($USD Millions)$(23.3) $(6.0) $(7.1)
Adjusted EBITDA ($USD Millions)$28.6 $30.7 $32.8
Adjusted EBITDA Margin %9.2% 9.8% 10.1%
Center Margin ($USD Millions)$97.8 $100.4 $109.4
Center Margin % of Revenue31.3% 32.1% 33.6%

EPS comparison (company disclosed quarterly in Q2/Q3; Q4 per-share not provided in press materials):

MetricQ2 2024Q3 2024Q4 2024
Net Loss per Share (Basic & Diluted, $)$(0.06) $(0.02) N/A (not disclosed)

KPIs and Operating Metrics:

KPIQ2 2024Q3 2024Q4 2024
Total Visits (Millions)1.969 1.973 2.033
Total Revenue per Visit ($)$158.6 $158.5 $160.1
Clinicians (Count)6,984 7,269 7,424

Context vs prior guidance (Q4 and FY 2024):

MetricPeriodCompany Guidance (Prior)ActualResult
Revenue ($M)Q4 2024$302.5–$322.5 $325.5 Beat (above high end)
Center Margin ($M)Q4 2024$89–$105 $109.4 Beat (above high end)
Adjusted EBITDA ($M)Q4 2024$18–$28 $32.8 Beat (above high end)
Revenue ($M)FY 2024$1,228–$1,248 $1,251.0 Beat (above high end)
Center Margin ($M)FY 2024$382–$398 $402.4 Beat (above high end)
Adjusted EBITDA ($M)FY 2024$105–$115 $119.7 Beat (above high end)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Revenue ($M)FY 2024$1,228–$1,248 (raised Nov 7) Actual $1,251.0 Beat vs guide
Center Margin ($M)FY 2024$382–$398 (raised Nov 7) Actual $402.4 Beat vs guide
Adjusted EBITDA ($M)FY 2024$105–$115 (raised Nov 7) Actual $119.7 Beat vs guide
Revenue ($M)Q4 2024$302.5–$322.5 (Nov 7) Actual $325.5 Beat vs guide
Center Margin ($M)Q4 2024$89–$105 (Nov 7) Actual $109.4 Beat vs guide
Adjusted EBITDA ($M)Q4 2024$18–$28 (Nov 7) Actual $32.8 Beat vs guide
Revenue ($M)FY 2025—$1,400–$1,440 Initial
Center Margin ($M)FY 2025—$440–$464 Initial
Adjusted EBITDA ($M)FY 2025—$130–$150 Initial
Revenue ($M)Q1 2025—$320–$340 Initial
Center Margin ($M)Q1 2025—$100–$114 Initial
Adjusted EBITDA ($M)Q1 2025—$27–$33 Initial

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3)Current Period (Q4)Trend
Payer rates & TRPVQ2: rate increases; warned of H2 step-down; Q3: outlier payer rate cut offset by broader increases 2025 rates roughly flat due to final outlier cut; margin expansion expected in 2026 Near-term pressure, normalization in 2026
Operating model & digital tools“One Stance” operating model launched; digital check-in rollout began; digital matching tool Digital check-in implemented in 21 of 33 states; national rollout by midyear Operational standardization progressing
Clinician growth & productivity6,984 → 7,269; stable retention; pipeline robust 7,424 (+12% y/y); visits +14% y/y; productivity slightly ahead Sustained growth
M&A appetiteFocus on disciplined capital deployment, fewer 2024 de novos, more 2025 Ready to resume disciplined acquisitions beyond tuck-ins Increasing appetite
Balance sheet & refinancingNot highlightedRefinancing reduced spread to 2.25% (from 3.75%); >$4M annual interest savings; revolver to $100M Improved flexibility
Collections & cyberattack impactDSO 49 days; working through Change Healthcare disruption DSO 37 days; strong FCF despite industry challenges Improving collections
AI/tech for clinician supportPiloting ML tools to ease documentation burden Emphasis on digital check-in; continued operational tooling Gradual tech deployment
Regulatory/macroCMS proposed ~3% rate cut for 2025; offsets via payer negotiations 2025 flat rates; 2026 low-mid single-digit rate improvement expected Manageable headwind

Management Commentary

  • “This was the first quarter in our history as a public company in which we delivered double-digit adjusted EBITDA margins.” — Dave Bourdon .
  • “We are now at a stage… where we are ready to return to acquisitions as early as this year… selective in pursuing acquisitions focused on capabilities, services or customer segments.” — Ken Burdick .
  • “Credit spread… reduced to 2.25%… down from 3.75%… annualized benefit… greater than $4 million per year.” — Dave Bourdon .
  • “We expect… in 2026… positive net income and earnings per share… and see a path to mid- to high-teens to 20% EBITDA margins.” — Dave Bourdon .

Q&A Highlights

  • Margin trajectory: 2025 margins roughly flat given rate headwind; management sees a path to 15–20% EBITDA margins over time with center margin improvement and G&A leverage .
  • Clinician recruiting: competitive backdrop remains intense; LifeStance’s employed model, pay stability (highlighted during Change Healthcare disruption), and operational support seen as differentiators .
  • Costs: center cost per visit declines from 2024 real estate consolidation won’t repeat in 2025; clinician wage increases will lift unit costs; G&A run-rate ~$77–$78M per quarter with seasonal payroll taxes in Q1 .
  • De novos and footprint: 25–30 de novos in 2025 (elevated due to six delayed openings); decisioning based on local demand, clinician recruiting, and center quality/size .
  • M&A environment: valuations more rational; focus on earnings vs revenue; disciplined approach to broadening capabilities/customer segments .

Estimates Context

  • Wall Street consensus (S&P Global) for Q4 2024 was unavailable at time of request due to S&P daily limit; therefore, comparisons vs sell-side consensus are not provided. We anchor performance vs company guidance and disclosed actuals .
  • Values in this recap are sourced from company filings and earnings materials; no S&P Global estimate values are presented.

Key Takeaways for Investors

  • Q4 beat across revenue, Center Margin, and Adjusted EBITDA, with the first double-digit margin quarter—evidence of operational momentum and disciplined execution .
  • FY 2024 delivered strong growth and profitability improvement; 2025 guide implies continued growth with flat rates near-term and a plan to offset margin pressure via G&A leverage .
  • Balance sheet and liquidity improved with refinancing (> $4M annual interest savings) and DSO reduction; robust FCF provides capacity for disciplined M&A and de novos .
  • Near-term watch items: final outlier payer rate decrease effects on TRPV in H1’25, G&A seasonality in Q1, clinician compensation-driven unit cost increases, and execution of digital check-in rollout .
  • Medium-term thesis: as rate headwinds abate in 2026, management targets mid-teens revenue growth and margin expansion, with a credible path to positive net income and 15–20% EBITDA margins .
  • Strategic update: leadership transition to Bourdon, readiness for disciplined acquisitions beyond tuck-ins, and continued focus on hybrid care scaling and tech-enabled workflows .
  • Trading implications: stock narrative should reflect execution consistency (9 straight quarters meeting/exceeding commitments), margin inflection, and improved financial flexibility; monitor 2025 rate/trends and H2 momentum as potential catalysts .